Zachary H Cooper

US Patent:

20200317803, Oct 8, 2020

Filed:

Apr 1, 2020

Appl. No.:

16/837477

Inventors:

- GAITHERSBURG MD, US
Zachary COOPER - GAITHERSBURG MD, US
Anis KHAN - GAITHERSBURG MD, US
Judson ENGLERT - GAITHERSBURG MD, US
Nancy Kathryn MUELLER - Gaithersburg MD, US
Charles FERTÉ - GAITHERSBURG MD, US
Pablo MARTINEZ RODRIGUEZ - GAITHERSBURG MD, US

International Classification:

C07K 16/28
A61K 31/555
A61K 31/519
A61K 31/513
C07K 16/22
A61K 31/337
A61K 33/24
A61K 31/7068
A61P 35/00

Abstract:

This disclosure relates to a monoclonal antibody directed against CD73 or an antigen-binding fragment thereof, and the use of such antibody or antigen-binding fragment thereof in the treatment of tumors. The disclosure also relates to methods for the treatment of tumors comprising administering to a patient in need thereof an anti-CD73 antibody or antigen-binding fragment thereof in combination with a monoclonal antibody directed against programmed death-ligand 1 (PD-L1) also known as B7 homolog 1 (B7-H1), or an antigen-binding fragment thereof. The disclosure also relates to methods for the treatment of tumors comprising administering to a patient in need thereof an anti-CD73 antibody or antigen-binding fragment thereof in combination with a PD-L1 antibody or an antigen-binding fragment thereof and chemotherapy.